Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer.
Saved in:
| Title: | Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer. |
|---|---|
| Authors: | Liu W; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.; National Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China., Huo G; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.; National Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China., Chen P; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.; National Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China. |
| Source: | Frontiers in public health [Front Public Health] 2024 Feb 15; Vol. 12, pp. 1213318. Date of Electronic Publication: 2024 Feb 15 (Print Publication: 2024). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Frontiers Editorial Office Country of Publication: Switzerland NLM ID: 101616579 Publication Model: eCollection Cited Medium: Internet ISSN: 2296-2565 (Electronic) Linking ISSN: 22962565 NLM ISO Abbreviation: Front Public Health Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38435286 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Liu+W%22">Liu W</searchLink>; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.; National Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Huo+G%22">Huo G</searchLink>; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.; National Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Chen+P%22">Chen P</searchLink>; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.; National Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101616579%22">Frontiers in public health</searchLink> [Front Public Health] 2024 Feb 15; Vol. 12, pp. 1213318. <i>Date of Electronic Publication: </i>2024 Feb 15 (<i>Print Publication: </i>2024). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Editorial+Office%22">Frontiers Editorial Office </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101616579 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2296-2565 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2222962565%22">22962565 </searchLink><i>NLM ISO Abbreviation: </i>Front Public Health <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38435286 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3389/fpubh.2024.1213318 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1213318 Titles: – TitleFull: Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Liu W – PersonEntity: Name: NameFull: Huo G – PersonEntity: Name: NameFull: Chen P IsPartOfRelationships: – BibEntity: Dates: – D: 15 M: 02 Text: 2024 Feb 15 Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 2296-2565 Numbering: – Type: volume Value: 12 Titles: – TitleFull: Frontiers in public health Type: main |
| ResultId | 1 |
